10 Toca 5: Toca 511 combined with Toca FC versus standard of care in patients undergoing planned resection for recurrent glioblastoma or anaplastic astrocytoma
Gelareh Zadeh(University of Toronto), TF Cloughesy, Tobias Walbert(Henry Ford Health System), Tiffany T. Montellano(Kura Oncology (United States)), Daniela A. Bota(University of California, Irvine), Jay‐Jiguang Zhu(The University of Texas Health Science Center at Houston), Thian Kheoh(Janssen (United States)), L Kim, Fábio M. Iwamoto(Columbia University), Arabinda K. Das, James Perry, S. Sully, Michael Salacz(The University of Kansas Cancer Center), Kevin Petrecca(McGill University Health Centre)
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
June 1, 2018
Cited by 2
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
Intraoperative brain cancer detection with Raman spectroscopy in humans
|Science Translational Medicine|2015|625
Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy
|Nature Communications|2020|601